Dr. Reddy's Laboratories (RDY) PT Raised to $40 at Barclays
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts RDY Hot Sheet
Price: $14.77 +3.29%
Rating Summary:
8 Buy, 2 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 17 | Down: 29 | New: 13
Rating Summary:
8 Buy, 2 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 17 | Down: 29 | New: 13
Join SI Premium – FREE
Barclays analyst Balaji Prasad raised the price target on Dr. Reddy's Laboratories (NYSE: RDY) to $40.00 (from $39.00) while maintaining a Equalweight rating.
You May Also Be Interested In
- Procore Technologies, Inc (PCOR) PT Raised to $90 at BTIG
- Clear Secure Inc (YOU) PT Raised to $80 at Goldman Sachs
- CVS Health (CVS) PT Lowered to $103 at Jefferies
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
